Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Nvidia Options Price in $280 Billion Earnings Swing 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Trump Buys SpaceX Shares After Record IPO 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Add as a preferred source on Google
WALTHAM, Mass., April 26, 2018 -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018, before the U.S. financial markets open.
The Company will host a conference call on Thursday, May 10, 2018 at 8:30 a.m. EDT. To access the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “8376199” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com, or by clicking here. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the call.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
